A Pipeline Shaped by Innovation
All of our programs are first-in-class and internally generated, each representing an opportunity to make a transformational impact across numerous diseases with high unmet need.
IND=investigational new drug.
POC=proof-of-concept.
sHLH=secondary hemophagocytic lymphohistiocytosis.
T-ALL=T cell acute lymphoblastic leukemia.
TCL=T cell lymphoma.
POC=proof-of-concept.
IND=investigational new drug.
sHLH=secondary hemophagocytic lymphohistiocytosis.
TCL=T cell lymphoma.
T-ALL=T cell acute lymphoblastic leukemia.